TSO3 enters into a bought deal agreement for Cdn $16,000,000
/NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR DISSEMINATION IN THE
Ticker: TSX - TOS Shares Outstanding: 47,891,957
The Company has granted the Underwriters an over-allotment option (the "Over-Allotment Option"), exercisable for a period of 30 days following the closing of the Offering, to purchase up to an additional 15% of the number of common shares issued from Treasury pursuant to the Offering, at the Offer Price.
Proceeds of the offering will be used by the Company for new product initiatives, working capital and general corporate purposes. Closing of the Offering is subject to certain conditions, including but not limited to, receipt of all necessary securities regulatory approvals, including the approval of the
This news release shall not constitute an offer to sell or the solicitation of an offer to buy the securities in any jurisdiction. The Common Shares have not been and will not be registered under the
TSO3 was founded in June of 1998, supported by a patented and unique technology for the sterilization of medical devices. This process uses ozone as the sterilizing agent and has been designed to allow the sterilization of heat and moisture-sensitive medical devices in healthcare settings.
The STERIZONE(R) Sterilization Process sterilizes large loads of medical devices quickly, cost-effectively, safely and in an eco-friendly way. This is in contrast to traditional gaseous low temperature sterilization methods which rely on toxic chemistry and require lengthy sterilization cycle times, or newer competitive oxidizing sterilizers which are costly to operate and limited in capability due to their load restrictions.
TSO3's first product, the STERIZONE(R) 125L Sterilizer has received clearance for commercialization from both Health
For more information about TSO3, visit the Company's Web site at www.tso3.com
The statements in this release and oral statements made by representatives of TSO3 relating to matters that are not historical facts (including, without limitation, those regarding the timing or outcome of any financing undertaken by TSO3) are forward-looking statements that involve certain risks, uncertainties and hypotheses, including, but not limited to, general business and economic conditions, the condition of the financial markets, the ability of TSO3 to obtain financing on favourable terms and other risks and uncertainties.
The TSX has neither approved nor disapproved the information contained herein and accepts no responsibility for it.For further information: Marc Boisjoli, CFO, (418) 651-0003, Ext. 228, Email: email@example.com; Caroline Côté, Director, Corporate Communications and Investor Relations, (418) 651-0003, Ext. 237, Email: firstname.lastname@example.org